Gruppo Oncologico Del Nord-ovest
Clinical trials sponsored by Gruppo Oncologico Del Nord-ovest, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New trial aims to shrink colorectal tumors before surgery with targeted drugs Results expected May 2027 (estimated)
-
Can a Three-Drug chemo cocktail before surgery stop biliary tract cancer from coming back?
Cure Recruiting nowThe PURITY trial compares giving a three-drug chemotherapy combination before surgery with going straight to surgery in people with biliary tract cancer that can be removed but has a high risk of returning. Participants are adults under 75 with confirmed, non-metastatic biliary t…
Phase 2/3 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
New trial aims to shrink colorectal tumors before surgery with targeted drugs
Disease control Recruiting nowThis study tests whether giving a short course of targeted drugs before surgery can improve outcomes for people with colorectal cancer that can be removed. About 197 participants will receive a treatment matched to their tumor's genetic makeup, followed by standard surgery. The g…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can switching chemo cocktails extend lives in pancreatic cancer?
Disease control Recruiting nowResearchers are comparing two chemotherapy approaches for people with advanced pancreatic cancer that has not worsened after three months of initial treatment with mFOLFIRINOX. One group continues mFOLFIRINOX, while the other switches to gemcitabine plus nab-paclitaxel. The trial…
Phase 3 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Gut health boost may tame immunotherapy side effects in head and neck cancer
Disease control Recruiting nowThis study tests whether a postbiotic supplement (Postbiotix-HLA™) can reduce immune-related side effects in 45 people with recurrent or metastatic head and neck cancer who are receiving the immunotherapy drug pembrolizumab. Participants will take either the supplement or a place…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for advanced colorectal cancer: drug cocktail shows promise
Disease control Recruiting nowThis study tests a combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with HER-2 positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see how well the drugs shrink tumors. About …
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Immunotherapy boost for hard-to-treat bowel cancer?
Disease control Recruiting nowThis Phase 3 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (FOLFOXIRI) and bevacizumab helps people with a specific type of metastatic colorectal cancer live longer without their disease getting worse. The study enrolls 238 adults whose t…
Phase 3 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC